Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 3
1996 2
1997 4
1998 4
1999 10
2000 8
2001 10
2002 13
2003 5
2004 6
2005 2
2006 7
2008 2
2009 3
2010 2
2011 2
2012 3
2013 1
2015 3
2016 2
2017 1
2018 1
2019 1
2021 1
2022 1
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab.
[No authors listed] [No authors listed] 2023 Mar 18. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Mar 18. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999639 Free Books & Documents. Review.
Ado-Trastuzumab Emtansine.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999886 Free Books & Documents. Review.
Bevacizumab.
[No authors listed] [No authors listed] 2024 Apr 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 Apr 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000790 Free Books & Documents. Review.
Pertuzumab.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999650 Free Books & Documents. Review.
Omalizumab.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000860 Free Books & Documents. Review.
Next-Generation Therapeutics for IBD.
Löwenberg M, D'Haens G. Löwenberg M, et al. Curr Gastroenterol Rep. 2015 Jun;17(6):21. doi: 10.1007/s11894-015-0444-2. Curr Gastroenterol Rep. 2015. PMID: 26031830 Free PMC article. Review.
Here, we summarize the recent literature in the area of emerging therapies in the field of IBD, with specific focus on anti-integrin antibodies, such as vedolizumab (anti-alpha4beta7) and etrolizumab (anti-rhuMAb beta7), and the Janus kinase (JAK) inhi …
Here, we summarize the recent literature in the area of emerging therapies in the field of IBD, with specific focus on anti-integrin …
Anti-IgE (rhuMAb-E25) therapy.
Rohane PW. Rohane PW. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 1999;(93):253-5; discussion 255-6. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 1999. PMID: 11487882 No abstract available.
Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ. Milgrom H, et al. N Engl J Med. 1999 Dec 23;341(26):1966-73. doi: 10.1056/NEJM199912233412603. N Engl J Med. 1999. PMID: 10607813 Free article. Clinical Trial.
We studied the efficacy of rhuMab-E25 as a treatment for moderate-to-severe allergic asthma. ...After 20 weeks, serum free IgE concentrations decreased by a mean of more than 95 percent in both rhuMAb-E25 groups. The therapy was well tolerated. After 20 weeks, none …
We studied the efficacy of rhuMab-E25 as a treatment for moderate-to-severe allergic asthma. ...After 20 weeks, serum free IgE concen …
Omalizumab: a monoclonal anti-IgE antibody.
Belliveau PP. Belliveau PP. MedGenMed. 2005 Jan 27;7(1):27. MedGenMed. 2005. PMID: 16369332 Free PMC article. Review.
METHODS: MEDLINE, In-Process & Other Non-Indexed Citations, and EMBASE Drugs & Pharmacology were searched using olizumab, omalizumab, E25, rhuMAb-E25, and anti-IgE. Combinations of rhinitis, asthma, and IgE captured information on disease pathophysiology. .. …
METHODS: MEDLINE, In-Process & Other Non-Indexed Citations, and EMBASE Drugs & Pharmacology were searched using olizumab, omalizumab …
92 results